3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Leukemia
59
Precursor Cell Lymphoblastic Leukemia-Lymphoma
53
Lymphoma
49
Burkitt Lymphoma
39
Lymphoma, Large B-Cell, Diffuse
37
Lymphoma, Follicular
37
Myelodysplastic Syndromes
34
Lymphoma, Non-Hodgkin
34
Multiple Myeloma
32
Leukemia, Myeloid, Acute
31
Leukemia, Myeloid, Chronic-Phase
30
Leukemia, Myeloid, Accelerated Phase
28
Lymphoma, Large-Cell, Immunoblastic
27
Leukemia, Lymphocytic, Chronic, B-Cell
27
Hodgkin Disease
22
Blast Crisis
22
Lymphoma, Mantle-Cell
21
Lymphoma, B-Cell, Marginal Zone
21
Graft vs Host Disease
21
Neoplasms, Plasma Cell
20
Myeloproliferative Disorders
20
Dendritic Cell Sarcoma, Interdigitating
20
Recurrence
19
Leukemia, Myelomonocytic, Chronic
17
Leukemia, Biphenotypic, Acute
17
Congenital Abnormalities
17
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
15
Anemia, Refractory, with Excess of Blasts
15
Primary Myelofibrosis
13
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
13
Interventions
bavituximab
1
Ursodeoxycholic Acid
1
Steroids
1
Sorafenib
1
Sofosbuvir
1
Ribavirin
1
Prednisone
1
Mycophenolic Acid
1
Methylprednisolone Hemisuccinate
1
Methylprednisolone
1
Adrenal Cortex Hormones
1
3-(2-(2-tert-butylphenylaminooxalyl)aminopropionylamino)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Hepatitis
×
Methylprednisolone
×
Clear all
NCT04810156
2022-12-14
I-HEP
Herlev Hospital
Phase 2
Unknown
60 enrolled